From the Departments of Genetics,
§ Pharmacology and Cancer Biology, ¶ Microbiology,
and
Medicine, ** Howard Hughes Medical Institute, Duke University
Medical Center, Durham, North Carolina 27710
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Rapamycin is an immunosuppressive natural
product that inhibits the proliferation of T-cells in response to
nutrients and growth factors. Rapamycin binds to the peptidyl-prolyl
isomerase FKBP12 and forms protein-drug complexes that inhibit
signal transduction by the TOR kinases. The FKBP12 and TOR
proteins are conserved from fungi to humans, and in both organisms the
TOR signaling pathway plays a role in nutrient sensing. In response to
nitrogen sources or amino acids, TOR regulates both transcription and
translation, enabling cells to appropriately respond to
growth-promoting signals. Rapamycin is having a profound impact on
clinical medicine and was approved as an immunosuppressant for
transplant recipients in 1999. Ongoing clinical studies address new
clinical applications for rapamycin as an antiproliferative drug for
chemotherapy and invasive cardiology.
The TOR kinases are members of the phosphatidylinositol
3-kinase (PI-3K)1 superfamily
that regulate cell growth and differentiation in response to nutrients.
In complex with the prolyl isomerase FKBP12, the antifungal and
immunosuppressive natural product rapamycin binds and inhibits the TOR
kinases. Genetic studies in yeast and biochemical studies in mammalian
cells identified the highly conserved proteins, the FKBP12 prolyl
isomerase and the TOR kinase homologs, as the targets of rapamycin
(1-5). Treatment of yeast or mammalian cells with rapamycin inhibits
translational initiation of a subset of mRNAs.
In yeast cells, rapamycin induces profound changes in gene
transcription. Exposure of yeast cells to rapamycin represses
transcription of the genes required for ribosome biogenesis (6-8) and
induces the expression of genes involved in nitrogen utilization
(8-10). Rapamycin also blocks cell cycle progression and triggers
autophagy (11-13). Some of these functions are conserved between yeast
and mammals, but the details of their regulation by TOR may differ. Upstream factors regulating the TOR kinases are involved in detecting amino acids, nutrients, and growth factors. In summary the TOR kinases
function in a conserved signaling pathway that coordinates nutritional
and mitogenic signals and controls gene expression, protein
biosynthesis, and cell growth.
Rapamycin is a microbial natural product with potent
antiproliferative activity. Rapamycin blocks cell proliferation in
response to either nutrients or mitogens, including interleukin 2, interleukin 3, platelet-derived growth factor, epidermal growth
factor, and insulin. In vivo rapamycin binds with
high affinity to the prolyl isomerase FKBP12 to form an active
drug-protein toxin (1, 2). The targets of the FKBP12-rapamycin complex,
first identified in yeast, are the highly homologous Tor1 and Tor2
proteins (targets of rapamycin),
which directly interact with FKBP12-rapamycin (1, 3, 14-17).
Subsequent biochemical studies identified the mammalian TOR (mTOR)
homolog (5, 18-20). Other TOR homologs have been identified in the
human fungal pathogen Cryptococcus neoformans (TOR1), in the
fission yeast Schizosaccharomyces pombe (TOR1, TOR2), and in
Drosophila melanogaster (dTOR) (21-25). Thus TOR is
conserved from yeasts to flies to humans.
The TOR proteins are founding members of a family of large proteins
that bear resemblance to the PI-3K, named the PIK-related kinases,
which regulate cell cycle progression in response to extracellular or
intracellular stimuli. This family includes: the mammalian
phosphatidylinositol 3-kinase, Atm (ataxia telangiectasia mutated), Atr
(ataxia telangiectasia related), DNA-dependent protein kinase, and the yeast Mec1, Rad53, and Tel1 proteins (26). A characteristic of the PIK-related family is a C-terminal kinase domain,
which shares homology with both protein and lipid kinases.
In addition to the kinase domain, the TOR proteins contain an
FKBP12-rapamycin binding domain (FRB), a toxic effector domain, and an
N-terminal region that features multiple HEAT repeats (named after the
four proteins containing this sequence: huntington, elongation factor 3, the A subunit of type 2A
protein phosphatase (PP2A), and Tor) that are thought to
mediate protein-protein interactions (27) (Fig.
1). The FRB domain was initially
identified by mutations that confer dominant rapamycin resistance and
was later mapped to a region of ~100 amino acids (28-30). The FRB
domain binds the FKBP12-rapamycin complex in vitro, and the
crystal structure of the tripartite complex has been solved (28, 31).
Although rapamycin binding results in only partial inhibition of TOR
kinase activity, the importance of the FRB domain in TOR function is beginning to be defined. In human cells, microinjection of the FRB
domain blocks cell cycle progression in the G1 phase (32). Similarly, the central TOR toxic domain inhibits cell growth when overexpressed in yeast (33). Tor1 mutants deleted for either the FRB or
the toxic domain lack kinase activity and fail to complement tor1 mutations in yeast (33).
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
TOR Kinases Are Targets...
TOR Controls Cellular Responses...
Transcriptional Regulation by...
Regulation of TOR Kinase...
Clinical Perspective
REFERENCES
TOR Kinases Are Targets of the Immunosuppressant Rapamycin
TOP
ABSTRACT
INTRODUCTION
TOR Kinases Are Targets...
TOR Controls Cellular Responses...
Transcriptional Regulation by...
Regulation of TOR Kinase...
Clinical Perspective
REFERENCES
View larger version (9K):
[in a new window]
Fig. 1.
Structure of the TOR kinases. The
positions of the known functional domains of the Tor kinase are
depicted, including the C-terminal kinase domain, the adjacent FRB
domain, the central toxic effector domain, the repressor domain that is
unique to mTOR, and the N-terminal HEAT repeats.
The yeast TOR toxic domain shares limited identity over a 240-amino acid region with several PIK family members, including the Atr, Rad3, Mei-41, and Atm proteins (33, 34). The dominant negative effects of the FRB and the toxic effector domains suggest these domains interact with upstream regulators or downstream effectors of the TOR cascade; however, their precise in vivo functions remain to be elucidated.
The TOR proteins exhibit protein kinase activity that is dependent on integrity of the kinase domain and inhibited by FKBP12-rapamycin or the PI-3K inhibitor wortmannin (33, 35-38). Both in vitro and in vivo studies revealed that mTOR phosphorylates and thereby inactivates the translational repressor protein PHAS-I (39, 40). Similarly, phosphorylation and activation of p70 S6 kinase (a regulator of translation) by mTOR has been reported (40). However, the sequences phosphorylated by mTOR in PHAS-I (S/TP) and in p70 S6 kinase (TY) do not conform to a consensus site. Thus, further studies will be needed to reconcile these results. Phosphorylation of both PHAS-I and p70 S6 kinase in response to mitogens is correlated with cell growth and proliferation and sensitive to rapamycin, indicating a role as downstream targets of mTOR (41, 42).
Genetic studies reveal that the TOR protein kinase activity is essential for in vivo TOR functions in yeast (16, 17, 33, 43). Furthermore, Tor1 displays an intrinsic, rapamycin-sensitive protein kinase activity with the mammalian translation repressor PHAS-I as a substrate (33). Finally, chimeric proteins with the kinase domain of mTOR fused to the N-terminal regions of yeast Tor1 or Tor2 provide TOR activity in yeast, underscoring the conservation of this domain throughout evolution (44).
Recently, a repressor domain has been identified in mTOR, which is
located on the C-terminal end of the kinase domain (45). This repressor
domain contains an amino acid residue, Ser-2448, which appears to be
phosphorylated by protein kinase B (AKT/PKB). Although an S2448A
mutation did not affect signaling by mTOR, a deletion of 30 amino
acids, including Ser-2448, enhances mTOR kinase activity and signaling.
This repressor domain is absent in the yeast TOR proteins and may be
unique to mTOR.
![]() |
TOR Controls Cellular Responses to Nutrients: Regulation of Translation |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
TOR is part of a signal transduction pathway that senses nutrients and regulates transcription, translation, and protein degradation. TOR mutations or inhibition by rapamycin elicits cellular responses characteristic of nutrient starvation, including inhibition of protein synthesis, transcriptional changes, cell cycle arrest, and autophagy (1, 3, 8, 10, 11, 17, 46).
The TOR proteins play a role in controlling translation initiation in
both mammalian and yeast cells (Fig. 2).
The mammalian TOR protein regulates translation by two independent
mechanisms involving direct or indirect activation of p70 S6 kinase and
inactivation of the translational repressor PHAS-I (Fig. 2). In
mammalian cells different growth stimuli, such as growth factors or
amino acids, result in phosphorylation and activation of p70 S6 kinase,
which in turn phosphorylates the ribosomal protein S6 (47-52).
Phosphorylation of the S6 protein facilitates translation of mRNAs
containing a 5'-polypyrimidine tract, including those encoding
ribosomal proteins, translation elongation factors, and growth control
proteins (53). PHAS-I binds to and inhibits eIF-4E, which is part of the multiprotein complex eIF-4F that functions in CAP
recognition and recruitment of ribosomes to the mRNA.
Phosphorylation of PHAS-I by mTOR prevents the association of PHAS-I
with eIF-4E, thereby promoting translation initiation (for reviews see
Refs. 54 and 55). Rapamycin treatment prevents activation of p70 S6
kinase and results in PHAS-I dephosphorylation, suggesting rapamycin blocks translation initiation by two mechanisms (47, 48, 54, 55) (Fig.
2). Yeast contains no direct structural homolog of the mammalian eIF-4E
binding protein PHAS-I. Recently, however, the yeast Eap1 protein was
identified based on its ability to interact with translation eIF-4E.
The Eap1 protein inhibits CAP-dependent translation,
and deletion of the EAP1 gene confers partial rapamycin resistance, suggesting Eap1 functions similar to mammalian PHAS-I (56).
|
The Drosophila TOR homolog, dTOR, plays a prominent role in cell growth and development (24, 25). Null mutations in the dTOR gene impair larval growth and reduce endoreplicating tissue. The phenotypic arrest point of dTOR mutant larvae is similar to wild-type larvae deprived of amino acids. dTOR mutations also mimic amino acid withdrawal in adult tissues. As in yeast and mammalian cells, p70 S6K kinase is a key effector of dTOR, and constitutive overexpression of p70 S6K rescues viability of dTOR mutant flies. In addition, dTOR was found to be required for PI-3K signaling, possibly linking mitogen-induced PI-3K signaling to nutrients (24, 25).
TOR control of translation in yeast cells involves regulation of PP2A
catalytic subunits, including Pph21, Pph22, and Sit4, which are known
to associate with Tap42 (57) (Fig. 2). The target of TOR in this
process appears to be Tap42. In accord with this view, certain
tap42 mutations confer resistance to rapamycin, and the
association of Tap42 with Pph21/Pph22 and Sit4 is prevented by entry
into stationary growth phase or by rapamycin (57). Furthermore, direct
phosphorylation of Tap42 by TOR has recently been reported (58).
Mammalian cells also contain a homolog of Tap42, the 4 protein,
which associates with PP2A phosphatases and modifies the substrate
specificity of PP2A (59, 60). However, the rapamycin sensitivity of the
4-PP2A association is at present controversial (59, 60).
Furthermore, the regulation of this complex may differ from that in
yeast as a recent study has suggested that PP2A is the target of mTOR
(61). Although evidence for direct phosphorylation of p70 S6 kinase by
mTOR has been presented, other studies failed to find significant
kinase activity of recombinant mTOR toward p70 S6 kinase (40, 61).
Instead, p70 S6 kinase was found in a complex with a fraction of PP2A,
and a model by which TOR phosphorylation of PP2A results in phosphatase
inactivation and thereby prevents S6 kinase dephosphorylation has been
proposed (61).
![]() |
Transcriptional Regulation by TOR |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Recent studies have uncovered a central role of TOR signaling in
the regulation of transcription (Fig. 3).
Earlier work established a role for TOR in rRNA and tRNA synthesis (7,
62). Although the targets of this regulation are not known, the TOR
pathway may act via PP2A in a manner analogous to translational
control. Mutations that affect PP2A function also impair rRNA and tRNA gene expression (63, 64).
|
Genome array studies reveal that ribosome biosynthetic genes expressed by PolII are also repressed by the addition of rapamycin in a manner that mimics nutritional limitation (8, 10, 65) (Fig. 3). Ribosomal protein (RP) genes are coordinately regulated in response to many environmental changes; however, the molecular details involving the transcription of RP genes are as yet unclear. Most RP gene promoters that contain binding sites for the activator/repressor protein, Rap1, and the transactivator, Abf1 (reviewed in Ref. 66). Studies have linked Rap1-mediated activation of RP genes to the cAMP pathway although the signaling events resulting in cAMP-induced transcription are at this time unknown (67, 68). The identification of Tor kinases as upstream regulators of RP genes provides a starting point to dissect regulatory events governing these genes and should provide insight to the interplay of the TOR and cAMP nutrient-stimulated signaling pathways.
Recently, the TOR pathway was shown to control the expression of the nitrogen catabolite repressed (NCR) genes, underscoring the central role of TOR in nitrogen sensing (8-10, 65). The NCR genes are repressed by preferred nitrogen sources, such as glutamine or ammonia, and derepressed by limiting or poor nitrogen sources, such as proline or urea. Regulatory factors involved in the repression or activation of these genes were tested as targets of the TOR kinases (8-10, 69). Many NCR genes are regulated by a set of GATA transcription factors including the transactivators Gln3 and Nil1 and by their inhibitor, Ure2. Both Gln3 and Ure2 were shown to be phosphoproteins; furthermore, these factors are rapidly dephosphorylated upon nitrogen limitation or rapamycin treatment (8-10).
Recent studies have shown that Tor, Gln3, and Ure2 form a complex and that Gln3 is directly phosphorylated by Tor in vitro (69). Mechanistically, this complex controls the activity of Gln3 by retaining it in the cytoplasm (9). Nitrogen limitation or rapamycin causes Gln3 to translocate into the nucleus, whereas Ure2 remains cytoplasmic. tap42-11 or sit4 mutations prevent rapamycin-induced nuclear import of Gln3, indicating that PP2A is involved in this function of TOR (9). In the resulting model, the TOR kinases and PP2A share the same substrates, providing stringent and dynamic control whereby the TOR kinase regulates the dephosphorylation of its direct substrates by also inhibiting the relevant phosphatase (Fig. 3).
A particular set of genes subject to nitrogen catabolite repression
includes genes required for the accumulation of precursors of
-ketoglutarate when yeast are grown on poor nitrogen sources such as
urea. Expression of these genes is controlled by the transactivators Rtg1 and Rtg3 and their positive regulator Rtg2. The TOR signaling pathway controls the activity of the Rtg proteins (65). Rapamycin or
poor nitrogen sources induce rapid nuclear import of Rtg1 and Rtg3 in
an Rtg2-dependent process. In this case, the importin
family member, Msn5, is required for the export of Rtg1 and Rtg3 as
msn5 mutations result in constitutive nuclear accumulation of these factors. Interestingly, an msn5 mutation does not
cause constitutive activation of the target genes for Rtg1 and Rtg3; instead, addition of rapamycin is still required for Rtg-directed gene
expression. Thus, the TOR pathway controls both nuclear localization of
the transactivators and downstream signaling events required for gene expression.
The control of nuclear import/export appears to be a general mechanism by which TOR regulates transcription (Fig. 3). Two additional transcription factors, Msn2 and Msn4, are constrained to the cytoplasm through interaction with a negative regulator (the 14-3-3 proteins Bmh1 and Bmh2) (9). The addition of rapamycin induces nuclear import of Msn2 and Msn4 and induction of stress-inducible genes regulated by these factors.
The emerging theme of Tor-regulated nuclear localization of
transcription factors may also extend to mammalian cells. The signal
transducer and activator of transcription, STAT3, is activated in
response to cytokines and translocates into the nucleus where it
directs transcription of its target genes. Recent studies indicate both
the nuclear localization and the ability to activate transcription may
be regulated by both mTor kinase and PP2A (70, 71).
![]() |
Regulation of TOR Kinase Activity by Nutrients |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cells control the rate of translation in response to energy and amino acids. Amino acid levels control amino acid biosynthesis, transport, and expression of the translation machinery in yeast and mammalian cells. Yeast cells use multiple mechanisms to determine the quality and abundance of amino acids and other nitrogen sources. Ammonium availability is sensed by an ammonium-specific permease, Mep2 (72). External amino acids are sensed by the amino acid receptor Ssy1 in a manner analogous to glucose sensing via the Snf3 and Rgt2 glucose sensors (73, 74). Internal amino acid availability is sensed by the general control response that detects uncharged tRNAs through the protein kinase Gcn2, and this pathway is conserved in mammals (70).
In mammalian cells, amino acids such as L-leucine stimulate
TOR kinase activity. Both the activity and phosphorylation states of
the mTOR downstream effector p70 S6K are decreased in response to amino
acid limitation and stimulated upon their readdition (50, 52).
Moreover, a rapamycin-resistant allele of p70 S6K causes cells to be
unresponsive to amino acid depletion (52). Amino acid alcohols that
inhibit amino acid charging of tRNA were found to suppress p70 S6K
activity, and a temperature-sensitive mutation of histidyl-tRNA
synthetase also impaired p70 S6K activity at the non-permissive
temperature (71). These results suggest aminoacylation of tRNAs may
regulate TOR in response to amino acids.
![]() |
Clinical Perspective |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Rapamycin was originally identified as a potent antifungal agent with an undesired side effect involving bone marrow suppression. The structural resemblance of rapamycin with the immunosuppressant FK506 prompted clinical studies to develop rapamycin as an immunosuppressive drug. During the last decade, the basic mechanisms of rapamycin drug action were elucidated and the targets FKBP12 and TOR identified, and rapamycin was approved by the Food and Drug Administration as an immunosuppressant in renal transplant recipients in August 1999.
Ongoing clinical studies address further uses of rapamycin, alone and
in combination with other immunosuppressants and in other transplant
settings. Rapamycin is synergistic with cyclosporin A and FK506 and
lacks the nephrotoxic effects of cyclosporin A or FK506, providing
renal sparing drug combinations. The rapamycin analog everlimus is in
phase III clinical trials as a immunosuppressant. Phase II clinical
trials of the rapamycin analog CCI-779 as a novel chemotherapy agent
for a variety of different solid tumors are ongoing. Finally, rapamycin
may also find a novel use in cardiology. Clinical studies in human
patients reveal that impregnating cardiac stents with rapamycin
inhibits proliferation and restenosis that commonly occur after
treatment of coronary artery disease. These clinical advances
illustrate the dramatic impact of rapamycin on modern medicine.
![]() |
FOOTNOTES |
---|
* This minireview will be reprinted in the 2001 Minireview Compendium, which will be available in December, 2001. This work was supported by K01 Career Development Award CA77075 from NCI, National Institutes of Health (to M. E. C.) and by R01 Award AI41937 from NIAID, National Institutes of Health.
Associate investigator of the Howard Hughes Medical Institute.
§§ To whom correspondence should be addressed: Dept. of Genetics, Box 3546, 322 CARL Bldg., Research Dr., Duke University Medical Center, Durham, NC 27710. Tel.: 919-684-2095; Fax: 919-684-5458; E-mail: carde004@mc.duke.edu.
Published, JBC Papers in Press, February 2, 2001, DOI 10.1074/jbc.R000034200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: PI-3K, phosphatidylinositol 3-kinase; mTOR, mammalian TOR; FRB, FKBP12-rapamycin binding domain; eIF, eukaryotic initiation factor; PP2A, type 2A protein phosphatase; RP, ribosomal protein; NCR, nitrogen catabolite repressed.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Heitman, J., Movva, N. R., and Hall, M. N. (1991) Science 253, 905-909[Medline] [Order article via Infotrieve] |
2. | Koltin, Y., Faucette, L., Bergsma, D. J., Levy, M. A., Cafferkey, R., Koser, P. L., Johnson, R. K., and Livi, G. P. (1991) Mol. Cell. Biol. 11, 1718-1723[Medline] [Order article via Infotrieve] |
3. | Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., and Hall, M. N. (1993) Cell 73, 585-596[Medline] [Order article via Infotrieve] |
4. | Bram, R. J., Hung, D. T., Martin, P. K., Schreiber, S. L., and Crabtree, G. R. (1993) Mol. Cell. Biol. 13, 4760-4769[Abstract] |
5. | Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. (1994) Cell 78, 35-43[Medline] [Order article via Infotrieve] |
6. |
Powers, T.,
and Walter, P.
(1999)
Mol. Biol. Cell
10,
987-1000 |
7. |
Zaragoza, D.,
Ghavidel, A.,
Heitman, J.,
and Schultz, M. C.
(1998)
Mol. Cell. Biol.
18,
4463-4470 |
8. |
Cardenas, M. E.,
Cutler, N. S.,
Lorenz, M. C.,
Como, C. J. D.,
and Heitman, J.
(1999)
Genes Dev.
13,
3271-3279 |
9. | Beck, T., and Hall, M. N. (1999) Nature 402, 689-692[CrossRef][Medline] [Order article via Infotrieve] |
10. |
Hardwick, J. S.,
Kuruvilla, F. G.,
Tong, J. K.,
Shamji, A. F.,
and Schreiber, S. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14866-14870 |
11. |
Noda, T.,
and Ohsumi, Y.
(1998)
J. Biol. Chem.
273,
3963-3966 |
12. |
Kamada, Y.,
Funakoshi, T.,
Shintani, T.,
Nagano, K.,
Ohsumi, M.,
and Ohsumi, Y.
(2000)
J. Cell Biol.
150,
1507-1513 |
13. |
Abeliovich, H.,
Dunn, W. A.,
Kim, J.,
and Klionsky, D. J.
(2000)
J. Cell Biol.
151,
1025-1034 |
14. | Helliwell, S. B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R., and Hall, M. N. (1994) Mol. Biol. Cell 5, 105-118[Abstract] |
15. | Cafferkey, R., Young, P. R., McLaughlin, M. M., Bergsma, D. J., Koltin, Y., Sathe, G. M., Faucette, L., Eng, W.-K., Johnson, R. K., and Livi, G. P. (1993) Mol. Cell. Biol. 13, 6012-6023[Abstract] |
16. | Zheng, X.-F., Fiorentino, D., Chen, J., Crabtree, G. R., and Schreiber, S. L. (1995) Cell 82, 121-130[Medline] [Order article via Infotrieve] |
17. | Cardenas, M. E., and Heitman, J. (1995) EMBO J. 14, 5892-5907[Abstract] |
18. | Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994) Nature 369, 756-759[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Chiu, M. I.,
Katz, H.,
and Berlin, V.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12574-12578 |
20. |
Sabers, C. J.,
Martin, M. M.,
Brunn, G. J.,
Williams, J. M.,
Dumont, F. J.,
Wiederrecht, G.,
and Abraham, R. T.
(1995)
J. Biol. Chem.
270,
815-822 |
21. |
Cruz, M. C.,
Cavallo, L. M.,
Görlach, J. M.,
Cox, G.,
Perfect, J. R.,
Cardenas, M. E.,
and Heitman, J.
(1999)
Mol. Cell. Biol.
19,
4101-4112 |
22. | Weisman, R., Choder, M., and Koltin, Y. (1997) J. Bacteriol. 179, 6325-6334[Abstract] |
23. |
Weisman, R.,
and Choder, M.
(2000)
J. Biol. Chem.
276,
7027-7032 |
24. |
Zhang, H.,
Stallock, J. P.,
Ng, J. C.,
Reinhard, C.,
and Neufeld, T. P.
(2000)
Genes Dev.
14,
2712-2724 |
25. |
Oldham, S.,
Montagne, J.,
Radimerski, T.,
Thomas, G.,
and Hafen, E.
(2000)
Genes Dev.
14,
2689-2694 |
26. | Keith, C. T., and Schreiber, S. L. (1995) Science 270, 50-51[Medline] [Order article via Infotrieve] |
27. | Andrade, R., and Bork, P. (1995) Nat. Genet. 11, 115-116[Medline] [Order article via Infotrieve] |
28. | Chen, J., Zheng, X.-F., Brown, E. J., and Schreiber, S. L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4947-4951[Abstract] |
29. |
Lorenz, M. C.,
and Heitman, J.
(1995)
J. Biol. Chem.
270,
27531-27537 |
30. |
Stan, R.,
McLaughlin, M. M.,
Cafferkey, R. T.,
Johnson, R. K.,
Rosenberg, M.,
and Livi, G. P.
(1994)
J. Biol. Chem.
269,
32027-32030 |
31. | Choi, J., Chen, J., Schreiber, S. L., and Clardy, J. (1996) Science 273, 239-242[Abstract] |
32. |
Vilella-Bach, M.,
Nuzzi, P.,
Fang, Y.,
and Chen, J.
(1999)
J. Biol. Chem.
274,
4266-4272 |
33. |
Alarcon, C. M.,
Heitman, J.,
and Cardenas, M. E.
(1999)
Mol. Biol. Cell
10,
2531-2546 |
34. | Bosotti, R., Isacchi, A., and Sonnhammer, E. L. (2000) Trends Biochem. Sci. 25, 225-227[CrossRef][Medline] [Order article via Infotrieve] |
35. | Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and Schreiber, S. L. (1995) Nature 377, 441-446[CrossRef][Medline] [Order article via Infotrieve] |
36. | Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., and Abraham, R. T. (1996) EMBO J. 15, 5256-5267[Abstract] |
37. | Withers, D. J., Ouwens, D. M., Nave, B. T., van der Zon, G. C., Alarcon, C. M., Cardenas, M. E., Heitman, J., Maassen, J. A., and Shepherd, P. R. (1997) Biochem. Biophys. Res. Commun. 241, 704-709[CrossRef][Medline] [Order article via Infotrieve] |
38. |
Hara, K.,
Yonezawa, K.,
Kozlowski, M. T.,
Sugimoto, T.,
Andrabi, K.,
Weng, Q.-P.,
Kasuga, M.,
Nishimoto, I.,
and Avruch, J.
(1997)
J. Biol. Chem.
272,
26457-26463 |
39. |
Brunn, G. J.,
Hudson, C. C.,
Sekulic, A.,
Williams, J. M.,
Hosoi, J.,
Houghton, P. J.,
Lawrence, J. C.,
and Abraham, R. T.
(1997)
Science
277,
99-101 |
40. |
Burnett, P. E.,
Barrow, R. K.,
Cohen, N. A.,
Snyder, S. H.,
and Sabatini, D. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1432-1437 |
41. |
Lin, T. A.,
Kong, X.,
Saltiel, A. R.,
Blackshear, P. J.,
and Lawrence, J. C.
(1995)
J. Biol. Chem.
270,
18531-18538 |
42. |
von Manteuffel, S. R.,
Gingras, A.-C.,
Ming, X.-F.,
Sonenberg, N.,
and Thomas, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4076-4080 |
43. |
Schmidt, A.,
Kunz, J.,
and Hall, M. N.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13780-13785 |
44. | Alarcon, C. M., Cardenas, M. E., and Heitman, J. (1996) Genes Dev. 10, 279-288[Abstract] |
45. |
Sekulic, A.,
Hudson, C. C.,
Homme, J. L.,
Yin, P.,
Otterness, D. M.,
Karnitz, L. M.,
and Abraham, R. T.
(2000)
Cancer Res.
60,
3504-3513 |
46. | Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., and Hall, M. N. (1996) Mol. Biol. Cell 7, 25-42[Abstract] |
47. | Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. (1992) Cell 69, 1227-1236[Medline] [Order article via Infotrieve] |
48. | Jefferies, H. B. J., Reinhard, C., Kozma, S. C., and Thomas, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4441-4445[Abstract] |
49. |
Blommaart, E. F.,
Luiken, J. J.,
Blommaart, P. J.,
van Woerkom, G. M.,
and Meijer, A. J.
(1995)
J. Biol. Chem.
270,
2320-2326 |
50. |
Fox, H. L.,
Pham, P. T.,
Kimball, S. R.,
Jefferson, L. S.,
and Lynch, C. J.
(1998)
Am. J. Physiol.
275,
C1232-C1238 |
51. |
Xu, G.,
Kwon, G.,
Marshall, C. A.,
Lin, T.-A.,
Lawrence, J. C., Jr.,
and McDaniel, M. L.
(1998)
J. Biol. Chem.
273,
28178-28184 |
52. |
Hara, K.,
Yonezawa, K.,
Weng, Q.-P.,
Kozlowski, M. T.,
Belham, C.,
and Avruch, J.
(1998)
J. Biol. Chem.
273,
14484-14494 |
53. |
Jefferies, H. B. J.,
Fumagalli, S.,
Dennis, P. B.,
Reinhard, C.,
Pearson, R. B.,
and Thomas, G.
(1997)
EMBO J.
16,
3693-3704 |
54. | Brown, E. J., and Schreiber, S. L. (1996) Cell 86, 517-520[Medline] [Order article via Infotrieve] |
55. | Lawrence, J. C., Jr., and Abraham, R. T. (1997) Trends Biochem. Sci. 22, 345-349[CrossRef][Medline] [Order article via Infotrieve] |
56. |
Cosentino, G. P.,
Schmelzle, T.,
Haghighat, A.,
Helliwell, S. B.,
Hall, M. N.,
and Sonenberg, N.
(2000)
Mol. Cell. Biol.
20,
4604-4613 |
57. | Di Como, C. J., and Arndt, K. T. (1996) Genes Dev. 10, 1904-1916[Abstract] |
58. |
Jiang, Y.,
and Broach, J. R.
(1999)
EMBO J.
18,
2782-2792 |
59. |
Murata, K.,
Wu, J.,
and Brautigan, D. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10624-10629 |
60. | Nanahoshi, M., Nishiuma, T., Tsujishita, Y., Hara, K., Inui, S., Sakaguchi, N., and Yonezawa, K. (1998) Biochem. Biophys. Res. Commun. 251, 520-526[CrossRef][Medline] [Order article via Infotrieve] |
61. |
Peterson, R. T.,
Desai, B. N.,
Hardwick, J. S.,
and Schreiber, S. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4438-4442 |
62. | Mahajan, P. B. (1994) Int. J. Immunopharmacol. 16, 711-721[CrossRef][Medline] [Order article via Infotrieve] |
63. | Stettler, S., Chiannilkulchai, N., Denmat, S. H.-L., Lalo, D., Lacroute, F., Sentenac, A., and Thuriaux, P. (1993) Mol. Gen. Genet. 239, 169-176[Medline] [Order article via Infotrieve] |
64. | van Zyl, W., Huang, W., Sneddon, A. A., Stark, M., Camier, S., Werner, M., Marck, C., Sentenac, A., and Broach, J. R. (1992) Mol. Cell. Biol. 12, 4946-4959[Abstract] |
65. |
Komeili, A.,
Wedaman, K. P.,
O'Shea, E. K.,
and Powers, T.
(2000)
J. Cell Biol.
151,
863-878 |
66. | Warner, J. R. (1999) Trends Biochem. Sci. 24, 437-440[CrossRef][Medline] [Order article via Infotrieve] |
67. | Klein, C., and Struhl, K. (1994) Mol. Cell. Biol. 14, 1920-1928[Abstract] |
68. | Neuman-Silberberg, F. S., Bhattacharya, S., and Broach, J. R. (1995) Mol. Cell. Biol. 15, 3187-3196[Abstract] |
69. |
Bertram, P. G.,
Choi, J. H.,
Carvalho, J.,
Ai, W.,
Zeng, C.,
Chan, T. F.,
and Zheng, X. F.
(2000)
J. Biol. Chem.
275,
35727-35733 |
70. |
Kilberg, M. S.,
Hutson, R. G.,
and Laine, R. O.
(1994)
FASEB J.
8,
13-19 |
71. |
Iiboshi, Y.,
Papst, P. J.,
Kawasome, H.,
Hosoi, J.,
Abraham, R. T.,
Houghton, P. J.,
and Terada, N.
(1999)
J. Biol. Chem.
274,
1092-1099 |
72. |
Lorenz, M. C.,
and Heitman, J.
(1998)
EMBO J.
17,
1236-1247 |
73. |
Iraqui, I.,
Vissers, S.,
Bernard, F.,
de Craene, J. O.,
Boles, E.,
Urrestarazu, A.,
and Andre, B.
(1999)
Mol. Cell. Biol.
19,
989-1001 |
74. | Klasson, H., Fink, G. R., and Ljungdahl, P. O. (1999) Mol. Cell. Biol. 19, 5404-5416 |